Using Predictive Intelligence to Uncover the Rare Disease Patient Journey
In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, explains the...
Using ML/AI to Find the Right Patients at the Right Time: A Conversation with AVEO Oncology
By: Dan Fisher, Principal, IPM.ai
Ganesh Rajaratnam, Senior Director of Commercial Operations,...
IPM.ai Recognized as One of the World’s Most Innovative Companies in 2022 by Fast Company
IPM.ai’s transformative approach to patient-finding for specialty and rare conditions captures the...
Ron Elwell, CEO and Founder of IPM.ai Wins MM+M’s Pinnacle Award
By: Dan Fisher, Principal, IPM.ai
Ron Elwell, CEO and founder of IPM.ai is a proud recipient of ...
Utilizing Augmented Intelligence to Drive Optimal Decisions Throughout the Specialty and Rare Disease Product Lifecycle
By: Dan Fisher, Principal, IPM.ai
Life sciences and healthcare companies that set out to pioneer...
A New Reference Model for Clinical Study Recruitment
By: Dan Fisher, Principal, IPM.ai
Conventional clinical study recruitment methods for rare diseases...
Real Chemistry's IPM.ai Expands Partnership with Datavant
San Francisco – Aug. 19, 2021 – Real Chemistry’s IPM.ai, the leader in uncovering undiagnosed and...
IPM.ai's Clinical Trial Recruitment Solution Featured in MM&M
By: Dan Fisher, Principal, IPM.ai
Allison Rhee of MM&M reports on IPM.ai's answer to patient...
IPM.ai Accelerates the Clinical Study and Commercialization of Precision Medicine
Targeted Approach Optimizes Clinical Study Recruitment of Medically-Eligible Patients Affected by...
Using Non-Traditional Data to Unlock Disease Insights & Improve Outcomes
By: Dan Fisher, Principal, IPM.ai
Though it’s not often discussed, the most difficult aspect of...